Skin Conditions & Dermatology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

This Phase 3 trial is testing ritlecitinib, a new daily oral medicine, for children aged 6 to 12 who have severe alopecia areata. This condition causes hair loss and can be very distressing for children and their families. If this treatment works, it could provide a new option for kids who have not had success with other therapies, potentially helping them regain hair and improve their quality of life.

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

This Phase 3 study is looking at amlitelimab, an injectable treatment for people 12 years and older with moderate-to-severe atopic dermatitis (AD) who did not respond well to previous biologic or oral JAK inhibitor treatments. Atopic dermatitis causes red, itchy, and inflamed skin, which can significantly affect daily life. This trial could lead to a new treatment for patients with limited options, helping to reduce symptoms and improve comfort over a period of up to 36 weeks.

Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers

This study is testing a mobile app that uses artificial intelligence to assist frontline health workers in diagnosing skin-related neglected tropical diseases, such as leprosy and Buruli ulcer, in Sub-Saharan Africa. Early and accurate diagnosis of these diseases can be challenging in underserved areas. If successful, this tool could speed up detection and treatment, improving health outcomes for many people in affected communities.

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

This Phase 3 trial is evaluating IPN10200, an injectable treatment aimed at reducing moderate to severe wrinkle-like lines between the eyebrows in adults. Wrinkles in this area can impact self-confidence and appearance. The study involves repeated treatments over up to 107 weeks, and if effective, IPN10200 could offer a new option for those looking to lessen these lines safely over time.

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for Treatment of Atopic Dermatitis

This Phase 2 trial tested a topical ointment containing tofacitinib for people aged 12 and older with atopic dermatitis. The ointment is designed to reduce itching and inflammation, common and troubling symptoms of the condition. Conducted over 8 weeks in the United States, this study could lead to a new topical treatment option for patients seeking relief from their skin symptoms.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.